201 related articles for article (PubMed ID: 28381184)
1. Integrated Cox's model for predicting survival time of glioblastoma multiforme.
Ai Z; Li L; Fu R; Lu JM; He JD; Li S
Tumour Biol; 2017 Apr; 39(4):1010428317694574. PubMed ID: 28381184
[TBL] [Abstract][Full Text] [Related]
2. Cancer survival classification using integrated data sets and intermediate information.
Kim S; Park T; Kon M
Artif Intell Med; 2014 Sep; 62(1):23-31. PubMed ID: 24997860
[TBL] [Abstract][Full Text] [Related]
3. A functional polymorphism in the pre‑miR‑146a gene influences the prognosis of glioblastoma multiforme by interfering with the balance between Notch1 and Notch2.
Liu R; Li W; Wu C
Mol Med Rep; 2015 Oct; 12(4):5475-81. PubMed ID: 26165719
[TBL] [Abstract][Full Text] [Related]
4. The functional Aquaporin 1 -783G/C-polymorphism is associated with survival in patients with glioblastoma multiforme.
El Hindy N; Rump K; Lambertz N; Zhu Y; Frey UH; Bankfalvi A; Siffert W; Sure U; Peters J; Adamzik M; Sandalcioglu IE
J Surg Oncol; 2013 Dec; 108(7):492-8. PubMed ID: 24014128
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of annexin VII expression in glioblastomas multiforme in humans.
Hung KS; Howng SL
J Neurosurg; 2003 Nov; 99(5):886-92. PubMed ID: 14609169
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme.
Bao ZS; Zhang CB; Wang HJ; Yan W; Liu YW; Li MY; Zhang W
CNS Neurosci Ther; 2013 Sep; 19(9):714-20. PubMed ID: 23663361
[TBL] [Abstract][Full Text] [Related]
7. Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.
Ilhan-Mutlu A; Wöhrer A; Berghoff AS; Widhalm G; Marosi C; Wagner L; Preusser M
J Neurooncol; 2013 May; 112(3):347-54. PubMed ID: 23420397
[TBL] [Abstract][Full Text] [Related]
8. A long non-coding RNA signature in glioblastoma multiforme predicts survival.
Zhang XQ; Sun S; Lam KF; Kiang KM; Pu JK; Ho AS; Lui WM; Fung CF; Wong TS; Leung GK
Neurobiol Dis; 2013 Oct; 58():123-31. PubMed ID: 23726844
[TBL] [Abstract][Full Text] [Related]
9. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of micro-RNA, gene expression, and survival of glioblastoma multiforme.
Huang YT; Hsu T; Kelsey KT; Lin CL
Genet Epidemiol; 2015 Feb; 39(2):134-43. PubMed ID: 25537983
[TBL] [Abstract][Full Text] [Related]
11. Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
El Hindy N; Bachmann HS; Lambertz N; Adamzik M; Nückel H; Worm K; Zhu Y; Sure U; Siffert W; Sandalcioglu IE
J Neurosurg; 2011 Jun; 114(6):1631-9. PubMed ID: 21250804
[TBL] [Abstract][Full Text] [Related]
12. Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme.
Simon M; Ludwig M; Fimmers R; Mahlberg R; Müller-Erkwoh A; Köster G; Schramm J
Neurosurgery; 2006 Nov; 59(5):1078-85; discussion 1085. PubMed ID: 17016233
[TBL] [Abstract][Full Text] [Related]
13. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.
Henriksen M; Johnsen KB; Andersen HH; Pilgaard L; Duroux M
Mol Neurobiol; 2014 Dec; 50(3):896-913. PubMed ID: 24619503
[TBL] [Abstract][Full Text] [Related]
15. An integrated mRNA and microRNA expression signature for glioblastoma multiforme prognosis.
Xiong J; Bing Z; Su Y; Deng D; Peng X
PLoS One; 2014; 9(5):e98419. PubMed ID: 24871302
[TBL] [Abstract][Full Text] [Related]
16. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
[TBL] [Abstract][Full Text] [Related]
17. Serum biomarkers for glioblastoma multiforme.
Quddusi A; Shamim MS
J Pak Med Assoc; 2019 Jun; 69(6):913-914. PubMed ID: 31201406
[TBL] [Abstract][Full Text] [Related]
18. The Influence of Distinct Regulatory miRNAs of the p15/p16/RB1/E2F Pathway on the Clinical Progression of Glioblastoma Multiforme.
Sippl C; Teping F; Ketter R; Braun L; Tremmel L; Schulz-Schaeffer W; Oertel J; Urbschat S
World Neurosurg; 2019 Dec; 132():e900-e908. PubMed ID: 31351207
[TBL] [Abstract][Full Text] [Related]
19. An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma.
Feng J; Kim ST; Liu W; Kim JW; Zhang Z; Zhu Y; Berens M; Sun J; Xu J
Cancer; 2012 Jan; 118(1):232-40. PubMed ID: 21713760
[TBL] [Abstract][Full Text] [Related]
20. Role of the GNAS1 T393C polymorphism in patients with glioblastoma multiforme.
El Hindy N; Lambertz N; Bachmann HS; Frey UH; Adamzik M; Zhu Y; Sure U; Siffert W; Sandalcioglu IE
J Clin Neurosci; 2011 Nov; 18(11):1495-9. PubMed ID: 21924916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
